一种针对转移性复发性儿童髓母细胞瘤的有效激酶抑制策略
该研究利用患者来源异种移植小鼠模型模拟标准化放化疗后人类髓母细胞瘤转移性复发,对640种激酶抑制剂进行高通量筛选,发现复发性第3组髓母细胞瘤脊柱细胞对选择性检查点激酶1(CHK1)抑制剂和血小板衍生生长因子受体β(PDGFRβ)小分子抑制剂敏感,抑制剂处理后的细胞髓母细胞瘤干细胞特性显著减少,小鼠在体外接受CHK1抑制剂治疗显示生存优势。
要点
- 复发性第3组髓母细胞瘤脊柱细胞对CHK1抑制剂和PDGFRβ抑制剂治疗敏感。
- 抑制剂处理后的细胞与治疗失败相关的髓母细胞瘤干细胞特性显著减少。
- 小鼠在体外接受CHK1抑制剂治疗显示生存优势。
核心结论
- 研究识别出CHK1和PDGFRβ抑制剂能有效靶向驱动治疗难治性转移的髓母细胞瘤细胞。
- 针对第3组髓母细胞瘤转移性复发的有效治疗研究有限,本工作凸显了治疗这些侵袭性肿瘤的有前景的治疗选择。
- 需要进一步研究来探究这些抑制剂的机制和建议的体内给药方案。
研究设计与样本
- 研究利用已建立的患者来源异种移植(PDX)小鼠适应治疗平台,模拟标准化放化疗后人类髓母细胞瘤转移性复发。
- 对从PDX模型小鼠脊柱分离的细胞和人胎儿神经干细胞进行640种激酶抑制剂的高通量筛选,以发现靶向这些治疗难治性转移细胞同时保护健康细胞的化合物。
- 通过血脑屏障通透性试验和额外体外实验帮助选择体内研究的顶级候选药物。
主要发现
- 复发性第3组髓母细胞瘤PDX脊柱细胞对选择性检查点激酶1(CHK1)抑制剂和血小板衍生生长因子受体β(PDGFRβ)小分子抑制剂治疗敏感。
- 抑制剂处理后的细胞显示与治疗失败相关的髓母细胞瘤干细胞特性显著减少。
- 小鼠在体外接受CHK1抑制剂治疗时显示生存优势。
局限性
- 需要进一步研究来探究这些抑制剂的机制和建议的体内给药方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Medulloblastomas (MBs) constitute the most common malignant brain tumor in children and adolescents. MYC-amplified Group 3 MBs are characterized by disease recurrence, specifically in the leptomeninges, whereby patients with these metastatic tumors have a mortality rate nearing 100%. Despite limited research on such tumors, studies on MB metastases at diagnosis suggest targeting kinases to be beneficial. METHODS: To identify kinase inhibitors that eradicate cells driving therapy evasion and tumor dissemination, we utilized our established patient-derived xenograft (PDX) mouse-adapted therapy platform that models human MB metastatic recurrences following standard chemoradiotherapy. High-throughput screens of 640 kinase inhibitors were conducted against cells isolated from mouse spines in the PDX model and human fetal neural stem cells to reveal compounds that targeted these treatment-refractory, metastatic cells, whilst sparing healthy cells. Blood-brain barrier permeability assays and additional in vitro experimentation helped select top candidates for in vivo studies. RESULTS: Recurrent Group 3 MB PDX spine cells were therapeutically vulnerable to a selective checkpoint kinase 1 (CHK1) inhibitor and small molecular inhibitor of platelet-derived growth factor receptor beta (PDGFRβ). Inhibitor-treated cells showed a significant reduction in MB stem cell properties associated with treatment failure. Mice also demonstrated survival advantage when treated with a CHK1 inhibitor ex vivo. CONCLUSION: We identified CHK1 and PDGFRβ inhibitors that effectively target MB cells fueling treatment-refractory metastases. With limited research on effective therapies for Group 3 MB metastatic recurrences, this work highlights promising therapeutic options to treat these aggressive tumors. Additional studies are warranted to investigate these inhibitors' mechanisms and recommended in vivo administration.
引用
- Adile AA, Bakhshinyan D, Suk Y, et al. An effective kinase inhibition strategy for metastatic recurrent childhood medulloblastoma. J Neurooncol. 2023. PMID: 37354357. doi:10.1007/s11060-023-04372-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。